[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100429681":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":24,"locations":10,"responsibleParty":29,"collaborators":10,"id":31,"slug":32,"hasResults":33,"nctId":34,"briefTitle":35,"officialTitle":36,"acronym":10,"eligibilityCriteria":37,"healthyVolunteers":38,"sex":39,"minAge":40,"maxAge":41,"enrollmentInfo":42,"targetDuration":10,"studyType":45,"phases":10,"briefSummary":46,"conditions":47,"keywords":50,"overallStatus":52,"whyStopped":10,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":10},{"fullName":5,"class":6},"Optimal Acuity Corporation","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Legally Blind Dry AMD Patients",null,"Legally Blind Dry AMD Patients with either unilateral or bilateral blindness",[13],"Device: Clear-K Low Vision Aid Treatment",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DEVICE","Clear-K Low Vision Aid Treatment","A Clear-K Low Vision Aid Device is used to produce small corneal shape and refraction changes in order to redirect light onto functional areas of the retina.",[9],[21],{"name":22,"affiliation":5,"role":23},"Michael Berry, PhD","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":10,"email":28},"CONTACT","831-869-1384","mberry177@gmail.com",{"type":30,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100429681","vision-improvement-for-legally-blind-dry-amd-patients-100429681",false,"NCT04875234","Vision Improvement for Legally Blind Dry AMD Patients","Vision Improvement for Legally Blind Dry Age-Related Macular Degeneration Patients","IInclusion Criteria:\n\n* Male or Female\n* Any race\n* Patient is at least 50 years old.\n* Patient must have dry AMD in the study eye.\n* Patient is legally blind due to AMD - i.e., has corrected distance visual acuity (CDVA) of 20\u002F125 or worse (45 letters; logMAR ≥ 0.80) in the study eye.\n* Patient has normal corneal surface topography on videokeratography (i.e., without distorted or unclear corneal mires).\n* Patient is not a contact lens wearer.\n* Patient is willing and able to comply with all examinations.\n* Patient must be competent to sign an informed consent form before study entry.\n\nExclusion Criteria:\n\n* Visually significant cataract in the study eye\n* Presence of a visually significant posterior capsule opacity if prior cataract surgery has been performed in the study eye\n* Any visually significant disease process in any ocular structure other than AMD that would affect vision in the study eye\n* Previous corneal surgery in the study eye\n* Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable as a candidate for study participation or may confound the outcome of the study",true,"ALL","50 Years","100 Years",{"count":43,"type":44},40,"ESTIMATED","OBSERVATIONAL","This retrospective observational study is intended to assess the feasibility of using a nonsignificant risk device for vision improvement for legally blind dry AMD patients.",[48,49],"Dry Age-related Macular Degeneration","Vision Impairment and Blindness",[51],"AMD, vision impairment, blindness","NOT_YET_RECRUITING","2023-03-21",{"date":55,"type":56},"2023-03-22","ACTUAL",{"date":58,"type":44},"2024-01",{"date":60,"type":44},"2026-12",{"name":5,"class":6}]